09:54 AM EST, 03/05/2024 (MT Newswires) -- DexCom ( DXCM ) said Tuesday it has real world evidence showing that the use of its automated insulin delivery system powered by its continuous glucose monitoring, or CGM, technology can reduce severe hypoglycemia and ketoacidosis in patients with type 1 diabetes over 12 months.

The company also said it has evidence showing a link between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes, adding it will present the data at the International Conference on Advanced Technologies and Treatments for Diabetes this week.

Dexcom ( DXCM ) also announced the phased launch of "direct to watch" connectivity for Apple ( AAPL ) Watch, allowing users of Dexcom's ( DXCM ) G7 CGM sensor to connect directly without carrying an iPhone. Global availability is planned for all G7 iOS users by the end of Q2, Dexcom ( DXCM ) added.

Price: 124.3, Change: +2, Percent Change: +1.64